Claims for Patent: 8,007,794

Summary for Patent: 8,007,794

Title:	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
Abstract:	The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
Inventor(s):	Zeller; Joerg (Ann Arbor, MI), Poulsen; Kristian T. (San Francisco, CA), Abdiche; Yasmina Noubia (Mountain View, CA), Pons; Jaume (San Bruno, CA), Collier; Sierra Leigh Jones (Menlo Park, CA), Rosenthal; Arnon (Woodside, CA)
Assignee:	Rinat Neuroscience Corporation (South San Francisco, CA)
Application Number:	12/093,638
Patent Claims:	1. An isolated antibody comprising a. CDR H1 as set forth in SEQ ID NO: 3: b. CDR H2 as set forth in SEQ ID NO: 4, or variants as shown in Table 6; c. CDR H3 as set forth in SEQ ID NO: 5: d. CDR L1 as set forth in SEQ ID NO: 6, or variants as shown in Table 6; e. CDR L2 as set forth in SEQ ID NO: 7, or variants as shown in Table 6; and f. CDR L3 as set forth in SEQ ID NO: 8; wherein the antibody has a binding affinity (K.sub.D) to human .alpha.-CGRP of 50 nM or less as measured by surface plasmon resonance at 37.degree. C. 2. The antibody according to claim 1, comprising a V.sub.H domain that is at least 90% identical in amino acid sequence to SEQ ID NO: 1. 3. The antibody according to claim 2, wherein the amino acid residue at position 99 of SEQ ID NO: 1 is L or is substituted by A, N, S, T, V or R, and wherein the amino acid residue at position 100 of SEQ ID NO: 1 is A, or is substituted by L, R, S, V, Y, C G, T, k, or P. 4. The antibody according to claim 1, comprising a V.sub.L domain that is at least 90% identical in amino acid sequence to SEQ ID NO: 2. 5. An isolated antibody comprising a V.sub.H domain comprising SEQ ID NO: 1 and a V.sub.L domain comprising SEQ ID NO: 2. 6. The antibody of claim 5, wherein the antibody is an IgG, an IgM, an IgE, an IgA, or an IgD molecule. 7. The antibody according to claim 5, comprising a heavy chain produced by the expression vector with ATCC Accession No. PTA-6867. 8. The antibody according to claim 5, comprising a light chain produced by the expression vector with ATCC Accession No. PTA-6866. 9. A pharmaceutical composition comprising the antibody according to claim 1 and a pharmaceutically acceptable excipient.

Details for Patent 8,007,794

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Teva Branded Pharmaceutical Products R&d, Inc.	AJOVY	fremanezumab-vfrm	Injection	761089	09/14/2018		2025-11-14
Teva Branded Pharmaceutical Products R&d, Inc.	AJOVY	fremanezumab-vfrm	Injection	761089	01/27/2020		2025-11-14

International Patent Family for US Patent 8,007,794

Country	Patent Number	Estimated Expiration
Australia	2006313434
Brazil	PI0618705
Canada	2626120
China	101309704